App-Quantinova.ai

The self-management of long-term conditions in the online era: an exploration of osteoarthritis-related videos on YouTube from 2017 in the United Kingdom

Amy J Curran - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Use of the Arthritis Research UK MSK HQ in an unselected population of attendees to a patient educationevent on osteoarthritis and joint pain

Sarah Levy - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Triamcinolone hexacetonide compared with triamcinolone acetonide in the management of osteoarthritis of the knee in adults a pilot audit study

Suresh Sudula - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Triamcinolone Hexacetonide

Relationships between markers of inflammation, grip strength and bone mineral density: findings from the Hertfordshire Cohort Study

Nicholas R Fuggle - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Estimation of fear of falling and confidence in patients with vertebral fractures: a five-year prospective study based on a cohort of older women

Usama Al-Sari - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

Evaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus

Chris Wincup - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Higher disease activity at baseline predicts disease progression and accrual of damage in Takayasu arteritis

Avinash Jain - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

N/A

Is ANCA-associated vasculitis more common in areas with more polluted air?

Hamzah Mahmood-Rao - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

N/A

Automated analysis of nailfold images from handheld devices

Michael Berks - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pilot study of polarisation sensitive optical coherence tomography as a biomarker for fibrosis in systemic sclerosis

Elizabeth Marjanovic - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Vascular calcification on hand and feet radiographs as a potential cardiovascular risk stratification tool: results from the Norfolk Arthritis Register

Leanne Gray - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Calcified vascular disease

N/A

Efficacyand safety of certolizumab pegol over four years in psoriatic arthritis patientswith and without concomitant use of DMARDs

Robert G Cooper - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Certolizumab pegol

Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies

Hector Chinoy - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved low disease activity related to psoriatic arthritis disease activity score

Laura C Coates - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

Serum vitamin D in ankylosing spondylitis and axial spondylitis: a systematic review and meta-analysis

Sarah Almanea - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Ergocalciferol

Long-term improvements in physical function of disease-modifying anti-rheumatic drug/biologic-experienced and disease-modifying anti-rheumatic drug-naïve psoriatic arthritis subjects treated with apremilast

Philip J Mease - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Apremilast

Neuropathic-like pain is common in psoriatic arthritis

Anoopama Ramjeeawon - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission

Iain McInnes - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Real world experience of apremilast in treating psoriatic arthritis patients with multiple comorbidities

Antoni Chan - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Apremilast

Critical role of the prolyl 3-hydroxylase LEPREL1 in scleroderma-related fibrosis

Bahja Abdi Ahmed - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Filters

45280 Abstracts